薑黃素 Curcumin × 非酒精性脂肪肝 (NAFLD/MASLD)
結論：證據支持但有警示
L2 收錄 5 篇 2023–2025 年系統性回顧／統合分析，4 篇支持薑黃素顯著降低 ALT/AST，1 篇 (PMC11089474, n=975) 結果為 null，研究間異質性高、樣本小、劑型不一，屬「中等證據」。
B 🟡 B 初步證據 附警語發布 🚨 high — heavy affiliate marketing in TW community
L2 收錄 5 篇 2023–2025 年系統性回顧／統合分析，4 篇支持薑黃素顯著降低 ALT/AST，1 篇 (PMC11089474, n=975) 結果為 null，研究間異質性高、樣本小、劑型不一，屬「中等證據」。
L5b Mayo Clinic 與 L5a NCCIH 認可初步陽性訊號但仍強調證據不足；L5c Cleveland、L5d Harvard、L5e AASLD/EASL 主流臨床指引均未將薑黃素納入 NAFLD 治療建議，且 AASLD DILI Network 反而將薑黃／薑黃素列為已知具肝毒性風險的補充品之一。
整體屬代理終點（ALT/AST）有訊號、組織學與臨床終點未驗證、且本身對標靶器官有安全疑慮的中等證據，B 級為合理判定。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.60
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
B · 附警語發布
信心度
77%
證據方向大致一致
證據層級
E2
多篇高品質統合分析（≥2 篇一致）
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.603
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial
結論：NASH resolution was achieved in 62% (16/26) of the Meriva group vs 12% (3/25) placebo (RR 5.33, p=0.003), with fibrosis improvement >=1 stage in 50% vs 8% (RR 6.50, p=0.008) and regression of significant fibrosis in 42% vs 0% (p=0.02); primary endpoint met.
前往 PubMed Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial
結論：Ultrasound liver-fat improvement occurred in 78.9% of the curcumin group vs 27.5% of placebo (OR ~16.0, 95% CI 1.9-139.8, p=0.005), with significant reductions in ALT, AST, total cholesterol, LDL, triglycerides, glucose and HbA1c versus placebo.
前往 PubMed Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial
結論：Nano-curcumin (80 mg/day) did NOT improve fibrosis or steatosis versus placebo (both arms improved, no significant between-group difference; FIB-4 between-group p=0.135); only surrogate liver enzymes (ALT p<0.001, AST p=0.004, GGT p=0.043) improved versus placebo, so the primary fibrosis endpoint was not met.
前往 PubMed Does curcumin improve liver enzymes levels in nonalcoholic fatty liver disease? A systematic review, meta-analysis, and meta-regression
結論：Curcumin did NOT significantly change ALT and reduced AST only modestly, with high heterogeneity (p<0.01); meta-regression found longer trials and higher relative doses diminished any benefit, undercutting a robust enzyme effect.
前往 PubMed An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand
結論：Curcumin reduced AST (MD -3.90 U/L, 95% CI -5.97 to -1.82) and ALT (MD -5.61 U/L, 95% CI -9.37 to -1.85) and was associated with ultrasound steatosis resolution (RR 3.53, 95% CI 2.01-6.22), but liver histology/fibrosis was not assessed and trials were geographically narrow (Iran/Thailand).
前往 PubMed L4a US FDA
中性
— 本適應症無對應資料
L4b EU EFSA
謹慎
the Panel established an ADI for curcumin of 3 mg/kg bw/day 來源↗
L4c UK NHS
謹慎
Avoid turmeric and curcumin in individuals with bile duct obstruction, cholangitis, liver disease, gallstones, or any biliary disease. 來源↗
L4d TW TFDA / 衛福部
謹慎
薑黃素每人每日攝取量為每公斤體重0~3毫克，每日不超過200毫克為宜 來源↗
L4e WHO
中性
Rhizoma Curcumae Longae 來源↗
L5a NIH Office of Dietary Supplements
謹慎
We don't know enough to definitively conclude if turmeric or curcumin is beneficial for any health purposes. 來源↗
L5b Mayo Clinic
謹慎
Curcumin is an antioxidant found in turmeric. Research suggests that curcumin may reduce liver inflammation, fat and scarring. However, more research is needed. Though it can be tempting to try a supplement that promises to clean or 'detox' the liver, using this type of supplement usually isn't a good idea, and some supplements that claim to help the liver can actually harm it. 來源↗
L5c Cleveland Clinic
謹慎
Curcumin is what gives turmeric that bright, yellow color and it delivers antioxidants and has anti-inflammatory properties. More isn't always better, so be sure to talk to your healthcare provider before adding any supplements to your routine. 來源↗
L5d Harvard Health
謹慎
Make sure that none of your medications, herbs, and supplements are toxic to the liver; you can crosscheck your list with this LiverTox. 來源↗
L5e Specialty Society (condition-mapped)
謹慎
Data from 8 US centers in the Drug-Induced Liver Injury Network revealed that between 2004 and 2013, 15.5% (130/839) of hepatotoxicity cases were attributed to dietary and herbal supplements, with turmeric associated with [a notable number of] single-ingredient products. AASLD provides updates on herbal and dietary supplements that may potentially cause liver injury, including curcumin/turmeric. 來源↗
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽
TW 社群普遍認為薑黃素對護肝、輔助改善脂肪肝肝指數有幫助，但實際個人「有感」回饋偏少，多為轉貼新聞與營養師觀點；同時也有越來越多警示貼文提醒高劑量、配胡椒鹼或本身已有肝病者可能反而增加肝損傷風險。
💬社群實感
意見分歧
破解迷思 社群最常見的 5 個誤解
✓
事實誤以為薑黃素一定要配胡椒鹼吸收才有效，忽略胡椒鹼會放大肝臟負擔
✓
事實把『薑黃』、『薑黃粉』、『薑黃素萃取膠囊』混為一談，劑量差距極大
✓
事實認為吃薑黃素就能取代飲食控制與減重來治療脂肪肝
✓
事實誤信『天然=安全』，忽略已有國際肝損傷死亡案例通報
✓
事實脂肪肝肝指數高就猛補薑黃素，反而可能延誤就醫
🩹 社群通報的副作用
- 胃部不適、胃食道逆流復發
- 腹瀉與排便次數增加
- 頭暈、噁心（高劑量時）
- 罕見但已有特異質性肝損傷／急性肝衰竭通報
- 與抗凝血、降血脂藥物的交互作用疑慮
🏷️ 社群熱議品牌
依論壇被提及頻率，非銷售或品質排序。
- 達摩本草
- UNIQMAN
- BHK's
- DHC 濃縮薑黃
- 新紅薑黃先生
- PowerHero
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
- 減重（飲食調整與運動）
- 地中海飲食型態
- 減少或戒除酒精
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-nafld-INT-curcumin-001/",
"datePublished": "2026-06-09",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "薑黃素能改善非酒精性脂肪肝 (NAFLD/MASLD)",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 3,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟡 B 初步證據"
}
}